- < General Internal Medicine
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
By sjmartinez • January 23, 2025
Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B, Wang Y, Ba Y, Li N, Zhang R, Zhang J, Chen Y, Chen J, Huang M, Fu Y, Liu M, Liu Z, Zhao J, Li W, Wei J, Li C, Xu N, Guo Z, Cao B, Liu L, Nie P, Wan L, Sheng L, Liu Z, He Y, Gu K, Wu G, Wang W, Zhang F, Qiu W, Guo J, Ying J, Pan H, Xu H, Yuan Y, Bai Y, Wang Z, Xu J, Zhao X, Liu H, Zhang X, Dai W, Xu H, Liu M, Xie L, Tang Y, Jin J, Qu X, Fang X, Huang M, Chen H, Zheng Z, Wang Y, Wang D, Li X, Yu G, Liu H, Zhou Y, Zhong D, Zeng S, Kang M, Wang M, Gao Y, Li W, Wang Z, Zhang M, Zhang J, Li Q, Sun S, Zang A, Lin L, Xie M, Zhuang Z, Zhang T, Yao Z, Lu D, Liu W, Hu M, Wang ZM, Li B, Xia M, Zhang J, Ying X, Pardoll DM, Ji J. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat Med. 2025 Jan 22. doi: 10.1038/s41591-024-03450-4. Epub ahead of print. PMID: 39843940.
Related Posts
Redekop E, Wang Z, Kulkarni R, Pleasure M, Chin A, Hassanzadeh HR, Hill BL, Emami M, Speier WF, Arnold CW. Zero-shot medical event prediction using[...]
Pollack CE, Blackford AL, Craig TK, Fan Q, Hussaini SMQ, Chen KL, Polsky D, Katana Ogongo M, Warren JL, Gross CP, Yabroff KR. Federal Housing[...]
Amarsi A, Xu J, Chan J, Jiang YC, Omar AZ, Meghdadi Y, Doshi A, Xie A, Wu A. Bridging gaps throughout a patient's journey with[...]
